Shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) saw unusually-strong trading volume on Tuesday . Approximately 131,991 shares changed hands during trading, an increase of 13% from the previous session’s volume of 116,527 shares.The stock last traded at $8.79 and had previously closed at $8.18.

Several equities research analysts have weighed in on NVLS shares. Cowen and Company restated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Zacks Investment Research upgraded shares of Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Tuesday, July 12th. Piper Jaffray Cos. reiterated a “buy” rating and set a $16.00 price target on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. HC Wainwright reiterated a “buy” rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Finally, Raymond James Financial Inc. began coverage on shares of Nivalis Therapeutics in a report on Tuesday, September 13th. They set an “outperform” rating and a $20.00 price target for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.05.

The stock has a 50-day moving average of $6.32 and a 200 day moving average of $4.96. The company’s market capitalization is $139.37 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/nivalis-therapeutics-inc-nvls-sees-unusually-high-trading-volume.html

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings data on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. Analysts predict that Nivalis Therapeutics Inc. will post ($2.29) EPS for the current fiscal year.

In related news, CMO David Malcom Rodman sold 5,950 shares of Nivalis Therapeutics stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $4.66, for a total value of $27,727.00. Following the completion of the transaction, the chief marketing officer now directly owns 18,055 shares in the company, valued at approximately $84,136.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.00% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BVF Inc. IL raised its position in Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock worth $8,862,000 after buying an additional 379,700 shares in the last quarter. Sabby Management LLC increased its position in shares of Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock valued at $2,761,000 after buying an additional 158,463 shares during the last quarter. AXA increased its position in shares of Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock valued at $2,455,000 after buying an additional 139,652 shares during the last quarter. Opaleye Management Inc. increased its position in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $1,287,000 after buying an additional 160,000 shares during the last quarter. Finally, State Street Corp increased its position in shares of Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock valued at $186,000 after buying an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 83.12% of the company’s stock.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.